Investors

Company Profile

Founded in November 2012, ObsEva is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for serious conditions that compromise a woman’s reproductive health and pregnancy. We believe our expertise has led to the development of new and innovative therapies that have the potential to improve patient outcomes in reproductive health.

Financial Reports

Sorry, there are no financial reports available yet.

Investor presentations

HCW Presentation September 13, 2021

ObsEva-Corporate-Deck_HCW_Final-Download

Canaccord Presentation August 12, 2021

ObsEva-Corporate-Deck_CanaccordDownload

Wedbush Presentation August 11, 2021

ObsEva_Corporate-Deck-2021-WedbushDownload

HCW Presentation March 9, 2021

ObsEva-HCW-Conference-Slides_March 9, 2021Download

SVB Leerink Presentation Feb 24, 2021

ObsEva Fireside chat_SVB Leerink_Feb 2021Download

JPM Presentation Jan 14, 2021

ObsEva_JPM Deck_1_14_2021Download

Additional Phase 3 PRIMROSE 1 and 2 Study Results Confirming Sustained Efficacy and Continued Safety of linzagolix in the Treatment of Uterine Fibroids

P12 W52_76_10 Dec 2020Download

Investor Presentation Jefferies Virtual London Healthcare Conference November 18, 2020

ObsEva_November2020presentation_jefferies 18.11Download
1 2 3

Press Releases

ObsEva Announces Dismissal of Moratorium Proceedings

press release

December 19, 2022

Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange GENEVA, Switzerland – December 19, 2022 –…

Read more

ObsEva Evidences Compliance with Nasdaq’s Stockholder’s Equity Rule and Announces Moratorium Dismissal Request Filing

press release

December 14, 2022

Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange GENEVA, Switzerland – December 14, 2022 –…

Read more

ObsEva To Increase Issued Share Capital by Creating Additional Treasury Shares

press release

December 9, 2022

Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange GENEVA, Switzerland – December 9, 2022 –…

Read more
1 2 3 … 81

General Meetings

ObsEva Annual General Meeting 2022

May 18, 2022

Read more

ObsEva Annual General Meeting 2021

May 28, 2021

Read more
1 2 3 4

Upcoming Events

Year End 2022 Financial Results week of 06 March 2023

Event


    Read more
     

    Stock Information

    Latest Press Release

    ObsEva Announces Dismissal of Moratorium Proceedings

    Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange GENEVA, Switzerland – December 19, 2022 –…

    Read more

    Investor Contact



    Will Brown

    +1 (334) 313-2319

    will.brown@obseva.com

    Media Contact

    Media

    Shauna Dillon

    shauna.dillon@obseva.ch

    Contacts

    ObsEva Switzerland Office

    Chemin des Aulx,12

    1228, Plan-Les-Ouates, Geneva, Switzerland

    +41 (0)22 552 3840


    contact@obseva.ch

    Media

    Shauna Dillon

    shauna.dillon@obseva.ch

    Investor relations



    Will Brown

    +1 (334) 313-2319

    will.brown@obseva.com

    Clinical studies




    clinicaltrials@obseva.ch

    HR Office

    Will Brown


    will.brown@obseva.ch

    CEO Office

    +41 (0)22 552 1550


    shauna.dillon@obseva.ch

     

    Sign up for news

     
     

      * Type:


      InvestorHCPNursePayerHospital PharmacistRetail PharmacistOther












      Read our privacy policy here.


       

      Are you sure you want to leave ObsEva.com?

      We’re sorry to see you go. Choose one of the following actions to stay on the site or leave.

      Continue to link

      Disclaimer

      Note that the following information contains information on investigational medicinal products. These products have not yet been approved for marketing by the European Medicines Agency or the U.S. Food and Drug Administration and are still under development. Further additional investigations may be needed in order for the marketing authorization to be granted, which grant may depend on a variety of factors and is not guaranteed. Click on “return” if you do not wish to receive such information. By clicking on “continue” you acknowledge that you wish to receive scientific information on our investigational products.

      Continue

      Disclaimer

      Note that the following information contains information on investigational medicinal products. These products have not yet been approved for marketing by the European Medicines Agency or the U.S. Food and Drug Administration and are still under development. Further additional investigations may be needed in order for the marketing authorization to be granted, which grant may depend on a variety of factors and is not guaranteed. Click on “return” if you do not wish to receive such information. By clicking on “continue” you acknowledge that you wish to receive scientific information on our investigational products.

      Continue